Target Research Guide

CB1, explained simply with PubMed links

This page translates CB1 research into plain English: what scientists studied, what kind of evidence exists, where the source links are strong or limited, and which PubMed records support each bucket.

Launch set page

Read Evidence Overview Open Source Table

255research sources

60evidence buckets

PubMedlinked references

What this page is

A plain-English research page about CB1. It explains what researchers studied and links the PubMed or DOI sources.

How to use it

Read the overview first. If a sentence matters to you, open the PubMed link or source table below it.

Important limit

This page is education, not medical advice, dosing advice, or a recommendation to use cannabinoids.

Evidence Rows 339

Traceable statements carried into the source table.

Human Evidence 1

Rows where human participants, patients, or clinical evidence are visible.

Mechanisms 143

Biology, target, enzyme, receptor, or pharmacology rows.

Safety / Limits 21

Safety, tolerability, uncertainty, or insufficient-evidence context.

Evidence Overview

CB1 has research behind it, but the bucket matters.

This page currently indexes 255 research sources across 60 evidence bucket(s). Read it as a map of what researchers have studied, not as a single bottom-line instruction. PMID 33636308

Human evidence 1 evidence row

Human studies are separated from preclinical and mechanistic evidence so a reader can see where people were actually studied. PMID 33636308

Mechanisms 143 evidence rows

Mechanistic rows explain biological plausibility, receptor activity, enzyme activity, or pharmacology; they do not automatically prove an outcome in people. PMID 33636308

Safety and limits 21 evidence rows

Safety, tolerability, product quality, impairment, interactions, and higher-risk contexts stay visible instead of being treated as footnotes. PMID 33636308

Evidence Buckets

What the CB1 research is usually about

Jump to source-backed table

CB1

CB1 appears in rows about CB1 mechanisms. It currently draws from 28 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 33636308

CB1

CB1 appears in rows about CB1 mechanisms. It currently draws from 16 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

CB2

CB1 appears in rows about CB2 mechanisms. It currently draws from 13 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 39288632

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

CB1 appears in rows studying 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 12 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 26271952

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

CB1 appears in rows studying anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 8 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36150527

CB2

CB1 appears in rows about CB2 mechanisms. It currently draws from 7 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

Reader Map

Evidence buckets before the source table

Grouped for readability

Bucket	Plain-English meaning	Evidence posture	Starting source
CB1	Grouped source-backed rows focused on CB1, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (13), mechanistic or pharmacological (16)	PMID 33636308
CB1	Grouped source-backed rows focused on CB1, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (11), mechanistic or pharmacological (5)	PMID 12505686
CB2	Grouped source-backed rows focused on CB2, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (8)	PMID 39288632
2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Grouped source-backed rows focused on 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic and preclinical research summary: insufficient (6), mechanistic or pharmacological (5), preclinical (1)	PMID 26271952
anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Grouped source-backed rows focused on anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (6), mechanistic or pharmacological (2)	PMID 36150527
CB2	Grouped source-backed rows focused on CB2, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (4)	PMID 12505686
Pain-related outcomes	Grouped source-backed rows focused on Pain-related outcomes, collapsed into one reader-facing bucket before the full source table.	Mechanistic and preclinical research summary: insufficient (2), mechanistic or pharmacological (4), preclinical (1)	PMID 41680865
Receptor, target, metabolic, and pharmacology mechanisms	Grouped source-backed rows focused on Receptor, target, metabolic, and pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (2)	PMID 39598860

Safety Reading Notes

Read safety context beside the research guide.

The CB1 source set includes safety-context rows around 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 33636308

Mechanistic and preclinical research summary: insufficient (6), mechanistic or pharmacological (5), preclinical (1)

PubMed For Dummies Article

CB1 Evidence Review: the long-form source walk-through

Quick read

CB1 currently has 339 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 33636308
The evidence classes most visible in the row language are insufficient (174), mechanistic or pharmacological (147), preclinical (16), and preliminary human (2). PMID 39528623
The study-design language most visible in the row language is Narrative or expert review (154), Animal study (105), Cellular or in vitro study (38), and other mapped categories (21). PMID 39598860
The repeated topics are CB1 (57), CB2 (31), receptor, target, metabolic, or pharmacology mechanisms (28), receptor, target, or pharmacology mechanisms (18), and other mapped categories (205), which tells the reader where to start opening PubMed and DOI links. PMID 41680865

Start with the research question

CB1 is built from 339 source-backed evidence row(s) and 255 research source(s). The current evidence classes read as insufficient (174), mechanistic or pharmacological (147), preclinical (16), and preliminary human (2), and the study-design language most often reads as Narrative or expert review (154), Animal study (105), Cellular or in vitro study (38), and other mapped categories (21). PMID 33636308

The row-level question is not simply whether CB1 is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are CB1 (57), CB2 (31), receptor, target, metabolic, or pharmacology mechanisms (28), receptor, target, or pharmacology mechanisms (18), and other mapped categories (205). PMID 12505686

Human evidence 1 row

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 40270953

Preclinical evidence 14 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 32899626

Mechanistic evidence 143 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 30627539

Limits and uncertainty 195 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 30405366

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 41256665

Where this page has the most source density

The largest bucket surfaced for this page is CB1. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB1, which gives readers another way to see what the literature repeatedly circles. PMID 33636308

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 12505686

Bucket chapters: what the literature is circling

CB1

28 research sources 29 rows (806-860) Mechanistic research summary: insufficient (13), mechanistic or pharmacological (16)

CB1 appears in rows about CB1 mechanisms. It currently draws from 28 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 33636308

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 33636308

Evidence row 806
Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signa... PMID 33636308
Evidence row 860
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or... PMID 38482984

CB1

16 research sources 16 rows (814-862) Mechanistic research summary: insufficient (11), mechanistic or pharmacological (5)

CB1 appears in rows about CB1 mechanisms. It currently draws from 16 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 12505686

Evidence row 814
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or s... PMID 12505686
Evidence row 862
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or... PMID 16596773

CB2

13 research sources 13 rows (864-916) Mechanistic research summary: insufficient (5), mechanistic or pharmacological (8)

CB1 appears in rows about CB2 mechanisms. It currently draws from 13 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 39288632

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 39288632

Evidence row 13
CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats; evidence class: mechanistic or pharmacological (population or model: rats; study design: rat and pharmacological study). PMID 39528623
Evidence row 864
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 39288632
Evidence row 916
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain... PMID 41383775

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

12 research sources 12 rows (1078-1091) Mechanistic and preclinical research summary: insufficient (6), mechanistic or pharmacological (5), preclinical (1)

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 26271952

Evidence row 12
CBN increases REM sleep; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: REM sleep). PMID 39528623
Evidence row 1078
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharma... PMID 26271952
Evidence row 1091
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure:... PMID 38052772

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

8 research sources 8 rows (1063-1077) Mechanistic research summary: insufficient (6), mechanistic or pharmacological (2)

Evidence row 1063
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 36150527
Evidence row 1077
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 24325918

CB2

7 research sources 7 rows (868-908) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (4)

CB1 appears in rows about CB2 mechanisms. It currently draws from 7 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 12505686

Evidence row 868
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, sele... PMID 12505686
Evidence row 908
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, n... PMID 23960212

Pain-related outcomes

7 research sources 7 rows (684-694) Mechanistic and preclinical research summary: insufficient (2), mechanistic or pharmacological (4), preclinical (1)

CB1 appears in rows studying Pain-related outcomes. It currently draws from 7 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41680865

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41680865

Evidence row 684
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41680865
Evidence row 694
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 40046175

Receptor, target, metabolic, and pharmacology mechanisms

7 research sources 7 rows (563-579) Mechanistic research summary: insufficient (5), mechanistic or pharmacological (2)

CB1 appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 7 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 39598860

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 39598860

Evidence row 563
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: rece... PMID 39598860
Evidence row 579
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 41155621

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (1 row(s)), mechanistic evidence (143 row(s)), and safety/tolerability context (21 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 33636308

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 12505686

What this does and does not mean

It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 42139799
It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 42196303
It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 33230154

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 33636308

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 12505686

Source-reading checklist for CB1

Open the linked PubMed or DOI record. PMID 39968488
Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 31447649
Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 31897571
Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 24595502
Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 36916438

Source Notes

CB1 source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

Evidence row 10
CBN increases Total sleep time; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: total sleep time). PMID 39528623
Evidence class: preclinical; Study design: rat polysomnography study. Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
Evidence row 11
CBN increases NREM sleep; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: NREM sleep). PMID 39528623
Evidence class: preclinical; Study design: rat polysomnography study. Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
Evidence row 12
CBN increases REM sleep; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: REM sleep). PMID 39528623
Evidence class: preclinical; Study design: rat polysomnography study. Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
Evidence row 13
CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats; evidence class: mechanistic or pharmacological (population or model: rats; study design: rat and pharmacological study). PMID 39528623
Evidence class: mechanistic or pharmacological; Study design: rat and pharmacological study. Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
Evidence row 31
CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 39598860
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
Evidence row 35
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 38
THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 40270953
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.
Evidence row 39
THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 43
CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 30627539
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.
Evidence row 44
THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological (outcome measure: safety, effect, or mechanism claims). PMID 30405366
Evidence class: mechanistic or pharmacological. Source: Cannabis Therapeutics and the Future of Neurology.
Evidence row 75
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 41256665
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.
Evidence row 76
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 42139799
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.
Evidence row 79
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 80
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 81
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes). PMID 39968488
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.
Evidence row 119
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 31447649
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.
Evidence row 130
CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 31897571
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats.
Evidence row 133
CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: nausea-related or inflammation-related outcomes). PMID 24595502
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.
Evidence row 174
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 202
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 31325449
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.
Evidence row 203
CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34179865
Evidence class: preclinical; Study design: Human clinical study. Source: Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
Evidence row 204
THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 205
THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 25220897
Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Evidence row 206
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 39288632
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).
Evidence row 207
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33636308
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Oxa-adamantyl cannabinoids.
Evidence row 208
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 18537620
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Evidence row 210
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 30670965
Evidence class: insufficient; Study design: Narrative or expert review. Source: Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.
Evidence row 211
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 28826536
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
Evidence row 212
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 30767756
Evidence class: insufficient; Study design: Narrative or expert review. Source: New Insights in Cannabinoid Receptor Structure and Signaling.
Evidence row 213
THC modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 30550613
Evidence class: preclinical; Study design: Animal study. Source: Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.
Evidence row 214
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 216
THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 238
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33897066
Evidence class: preliminary human; Study design: Human clinical study. Source: Adverse Effects of Recreational and Medical Cannabis.
Evidence row 242
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 42076122
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.
Evidence row 253
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084
Evidence class: insufficient; Study design: Animal study. Source: Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.
Evidence row 254
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 23924692
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Evidence row 255
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 39657242
Evidence class: insufficient; Study design: Narrative or expert review. Source: A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.
Evidence row 256
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 42212209
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: Pharmaceutical formulations and biomedical applications.
Evidence row 258
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263
Evidence class: insufficient; Study design: Systematic review. Source: Cys-loop receptors on cannabinoids: All high?
Evidence row 261
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 22585736
Evidence class: preclinical; Study design: Animal study. Source: Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.
Evidence row 262
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 16107637
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.
Evidence row 263
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35091505
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Mu Opioid Receptors Acutely Regulate Adenosine Signaling in Striatal Glutamate Afferents.
Evidence row 268
Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 40016352
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations.
Evidence row 276
Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 16596771
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor signaling.
Evidence row 284
CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35306000
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
Evidence row 288
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 26698193
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
Evidence row 289
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 26271952
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Endocannabinoid System and its Modulation by Phytocannabinoids.
Evidence row 292
CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 17965195
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
Evidence row 294
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 17704824
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
Evidence row 303
THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 20047159
Evidence class: insufficient; Study design: Narrative or expert review. Source: FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Evidence row 306
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 24346263
Evidence class: preclinical; Study design: Animal study. Source: Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.
Evidence row 307
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39245706
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.
Evidence row 309
THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39747798
Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical Probes for Investigating the Endocannabinoid System.
Evidence row 312
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 21418147
Evidence class: insufficient; Study design: Narrative or expert review. Source: The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.
Evidence row 313
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 30075103
Evidence class: preclinical; Study design: Animal study. Source: Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
Evidence row 340
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 41008526
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.
Evidence row 341
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33851375
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids.
Evidence row 343
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33909195
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.
Evidence row 357
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 26698193
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
Evidence row 361
CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 362
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 440
THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 33228239
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
Evidence row 457
THC studied for Dependence and withdrawal; evidence class: insufficient (study design: Narrative or expert review; outcome measure: dependence or withdrawal outcomes). PMID 19367504
Evidence class: insufficient; Study design: Narrative or expert review. Source: Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence.
Evidence row 465
THC studied for Cognition and memory; evidence class: mechanistic or pharmacological (outcome measure: cognition or memory outcomes). PMID 24639045
Evidence class: mechanistic or pharmacological. Source: Acute administration of THC impairs spatial but not associative memory function in zebrafish.
Evidence row 475
THC studied for Pain-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 31332738
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of Medical Cannabis.
Evidence row 514
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 27428345
Evidence class: insufficient; Study design: Narrative or expert review. Source: [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].
Evidence row 517
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 518
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 36424484
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.
Evidence row 519
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 520
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 521
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 10036999
Evidence class: insufficient; Study design: Narrative or expert review. Source: The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis.
Evidence row 523
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 38673788
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.
Evidence row 524
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 36091813
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules.
Evidence row 525
CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 527
CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 39275884
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.
Evidence row 529
CBN studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 38673788
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.
Evidence row 533
CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 40568800
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons.
Evidence row 535
CBN studied for Pain-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes). PMID 36424484
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.
Evidence row 540
CBG studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 541
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 39598860
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
Evidence row 557
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36497400
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.
Evidence row 558
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
Evidence row 563
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 39598860
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
Evidence row 568
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 569
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 570
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25269802
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
Evidence row 571
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 42105814
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.
Evidence row 577
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40046175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
Evidence row 579
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 41155621
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models.
Evidence row 584
CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes). PMID 39598860
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
Evidence row 589
CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes). PMID 23415610
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.
Evidence row 593
CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes). PMID 35614947
Evidence class: insufficient; Study design: Narrative or expert review. Source: Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action.
Evidence row 601
CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Animal model mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: inflammation-related or immune outcomes). PMID 29562280
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.
Evidence row 607
CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 620
CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 621
CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 622
CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 42105814
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.
Evidence row 627
CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 36397993
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.
Evidence row 646
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 648
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
Evidence row 662
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35306000
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
Evidence row 663
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 664
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 667
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40046175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
Evidence row 671
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 31368508
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene is a cannabinoid CB2 receptor agonist.
Evidence row 675
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 39137108
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.
Evidence row 679
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 23373571
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.
Evidence row 684
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 686
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 689
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41256665
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.
Evidence row 690
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 42139799
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.
Evidence row 691
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 692
CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 694
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 40046175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
Evidence row 704
CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 711
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
Evidence row 721
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 723
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 35306000
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
Evidence row 735
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes). PMID 32904155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain.
Evidence row 736
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 40270953
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.
Evidence row 740
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 746
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 41947574
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.
Evidence row 750
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 25542687
Evidence class: insufficient; Study design: Human clinical study. Source: Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.
Evidence row 752
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Case report or case series; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37305187
Evidence class: mechanistic or pharmacological; Study design: Case report or case series. Source: Hair Regrowth with Novel Hemp Extract: A Case Series.
Evidence row 754
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 35303507
Evidence class: insufficient; Study design: Animal study. Source: Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents.
Evidence row 755
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 23712280
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
Evidence row 756
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 31549358
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
Evidence row 757
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 36280497
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.
Evidence row 760
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 761
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 763
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 764
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 766
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 767
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25257544
Evidence class: insufficient; Study design: Systematic review. Source: Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
Evidence row 768
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 16205722
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
Evidence row 769
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28087250
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoids in the treatment of epilepsy.
Evidence row 770
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 41008636
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.
Evidence row 771
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 30170189
Evidence class: mechanistic or pharmacological. Source: Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.
Evidence row 772
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 31454413
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.
Evidence row 775
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 23902479
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Evidence row 777
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25542687
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.
Evidence row 781
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 34500785
Evidence class: mechanistic or pharmacological. Source: An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.
Evidence row 784
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 788
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 31454413
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.
Evidence row 789
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 25542687
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.
Evidence row 793
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 26362774
Evidence class: preliminary human; Study design: Human clinical study. Source: The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.
Evidence row 796
THCV studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 798
THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 806
Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 33636308
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Oxa-adamantyl cannabinoids.
Evidence row 807
Cannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 18537620
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Evidence row 808
THC modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 809
HHC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40866700
Evidence class: mechanistic or pharmacological. Source: Crystal structures of agonist-bound human cannabinoid receptor CB1.
Evidence row 810
THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 35489334
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.
Evidence row 811
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 38101408
Evidence class: mechanistic or pharmacological. Source: Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism.
Evidence row 812
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40044849
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A cryptic pocket in CB1 drives peripheral and functional selectivity.
Evidence row 813
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 28527758
Evidence class: insufficient; Study design: Narrative or expert review. Source: Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.
Evidence row 814
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 12505686
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
Evidence row 815
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 27245890
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Assay of CB1 Receptor Binding.
Evidence row 816
THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 38830102
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.
Evidence row 817
Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 10469884
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid receptor ligands.
Evidence row 818
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 27879006
Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.
Evidence row 819
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 9974174
Evidence class: insufficient; Study design: Narrative or expert review. Source: The CB1 cannabinoid receptor in the brain.
Evidence row 820
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 34500853
Evidence class: insufficient; Study design: Narrative or expert review. Source: CB1 Cannabinoid Receptor Signaling and Biased Signaling.
Evidence row 821
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 30333554
Evidence class: insufficient; Study design: Narrative or expert review. Source: Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.
Evidence row 822
THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 22343625
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.
Evidence row 823
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 38675703
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.
Evidence row 824
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 16113085
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Allosteric modulation of the cannabinoid CB1 receptor.
Evidence row 825
THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 31968549
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
Evidence row 826
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 28103441
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Evidence row 827
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 26408156
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and Their Pharmacological Actions.
Evidence row 828
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 29355038
Evidence class: mechanistic or pharmacological. Source: The future of type 1 cannabinoid receptor allosteric ligands.
Evidence row 829
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 25162172
Evidence class: mechanistic or pharmacological. Source: Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).
Evidence row 830
HHC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 28678776
Evidence class: mechanistic or pharmacological. Source: Crystal structures of agonist-bound human cannabinoid receptor CB1.
Evidence row 831
Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 29355030
Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.
Evidence row 832
THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 26132518
Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic Cannabinoids.
Evidence row 833
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 39828030
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.
Evidence row 834
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 39695122
Evidence class: mechanistic or pharmacological. Source: Structural mechanism of CB1R binding to peripheral and biased inverse agonists.
Evidence row 835
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 41559687
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Targeting mechanosensitive cannabinoid receptor 1 with isoflavone prodrugs attenuates atherosclerotic endothelial dysfunction.
Evidence row 836
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40521518
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.
Evidence row 837
THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 33811300
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
Evidence row 838
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 31490743
Evidence class: insufficient; Study design: Narrative or expert review. Source: Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist.
Evidence row 839
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 30767756
Evidence class: insufficient; Study design: Narrative or expert review. Source: New Insights in Cannabinoid Receptor Structure and Signaling.
Evidence row 840
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 28527758
Evidence class: insufficient; Study design: Narrative or expert review. Source: Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.
Evidence row 841
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 20590557
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?
Evidence row 842
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 34050525
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.
Evidence row 843
THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 27086601
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid System: A Multi-Facet Therapeutic Target.
Evidence row 844
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 17895407
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a.
Evidence row 845
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31771126
Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities.
Evidence row 846
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 16570099
Evidence class: insufficient; Study design: Narrative or expert review. Source: The pharmacology of cannabinoid receptors and their ligands: an overview.
Evidence row 847
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 19939187
Evidence class: insufficient; Study design: Narrative or expert review. Source: Latest advances in cannabinoid receptor agonists.
Evidence row 848
THC modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 19285266
Evidence class: insufficient; Study design: Narrative or expert review. Source: Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
Evidence row 849
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31461639
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.
Evidence row 850
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 15550444
Evidence class: insufficient; Study design: Narrative or expert review. Source: The endocannabinoid system: physiology and pharmacology.
Evidence row 851
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 36088492
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism.
Evidence row 852
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 35429587
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment.
Evidence row 853
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 40855505
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models.
Evidence row 854
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31491589
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Adipocyte cannabinoid CB1 receptor deficiency alleviates high fat diet-induced memory deficit, depressive-like behavior, neuroinflammation and impairment in adult neurogenesis.
Evidence row 855
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 25967266
Evidence class: insufficient; Study design: Narrative or expert review. Source: Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.
Evidence row 856
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 27828947
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A cannabinoid link between mitochondria and memory.
Evidence row 857
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 39300547
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome.
Evidence row 858
THC modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31165913
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species.
Evidence row 859
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 35595026
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus.
Evidence row 860
Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 38482984
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Adenosine receptors are the on-and-off switch of astrocytic cannabinoid type 1 (CB1) receptor effect upon synaptic plasticity in the medial prefrontal cortex.
Evidence row 861
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 36613469
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.
Evidence row 862
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 16596773
Evidence class: insufficient; Study design: Narrative or expert review. Source: Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice.
Evidence row 863
THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 864
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 39288632
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).
Evidence row 865
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 18537620
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Evidence row 866
THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 26698193
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
Evidence row 867
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 31368508
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene is a cannabinoid CB2 receptor agonist.
Evidence row 868
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 12505686
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
Evidence row 869
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 10469884
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid receptor ligands.
Evidence row 871
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 40271066
Evidence class: mechanistic or pharmacological. Source: A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay.
Evidence row 872
Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 28826535
Evidence class: insufficient; Study design: Narrative or expert review. Source: Functional Selectivity at Cannabinoid Receptors.
Evidence row 873
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 9336020
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid CB1 and CB2 receptors.
Evidence row 874
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 26124120
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.
Evidence row 875
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 34684770
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Spicy Story of Cannabimimetic Indoles.
Evidence row 876
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 30639103
Evidence class: mechanistic or pharmacological. Source: Crystal Structure of the Human Cannabinoid Receptor CB2.
Evidence row 877
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 32004460
Evidence class: mechanistic or pharmacological. Source: Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.
Evidence row 880
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 33749323
Evidence class: mechanistic or pharmacological. Source: CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.
Evidence row 883
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16563625
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor mediation of antinociception.
Evidence row 886
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 27608434
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats.
Evidence row 889
Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 38886185
Evidence class: insufficient; Study design: Narrative or expert review. Source: Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).
Evidence row 890
Anandamide modulates CB2; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16678907
Evidence class: insufficient; Study design: Narrative or expert review. Source: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
Evidence row 893
THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 29980914
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
Evidence row 894
Anandamide modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16596776
Evidence class: insufficient; Study design: Narrative or expert review. Source: Structural requirements for cannabinoid receptor probes.
Evidence row 901
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 36475439
Evidence class: mechanistic or pharmacological. Source: Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation.
Evidence row 903
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 18615177
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.
Evidence row 906
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 37286073
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.
Evidence row 907
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 26824325
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.
Evidence row 908
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 23960212
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.
Evidence row 911
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 12823482
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.
Evidence row 913
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 36583304
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation.
Evidence row 914
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41875735
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.
Evidence row 916
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41383775
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy.
Evidence row 922
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 18247131
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.
Evidence row 926
Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 28826536
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
Evidence row 927
THC modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 929
Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35862111
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.
Evidence row 932
Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 26669245
Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
Evidence row 933
Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 27835801
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor ligand bias: implications in the central nervous system.
Evidence row 934
Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 20370712
Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Evidence row 935
CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35083862
Evidence class: insufficient; Study design: Narrative or expert review. Source: A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).
Evidence row 936
CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17704827
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.
Evidence row 938
THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17876300
Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55: a new member of the cannabinoid receptor clan?
Evidence row 939
THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 20298715
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological characterization of GPR55, a putative cannabinoid receptor.
Evidence row 940
CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17876302
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The orphan receptor GPR55 is a novel cannabinoid receptor.
Evidence row 943
CBD modulates GPR55; evidence class: mechanistic or pharmacological (outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 36016551
Evidence class: mechanistic or pharmacological. Source: Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors.
Evidence row 944
Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 28826536
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
Evidence row 945
Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 27835801
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor ligand bias: implications in the central nervous system.
Evidence row 947
Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 34676329
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in Gynecological Diseases.
Evidence row 948
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 42114685
Evidence class: insufficient; Study design: Narrative or expert review. Source: Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.
Evidence row 949
THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29902723
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.
Evidence row 952
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29098189
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.
Evidence row 953
Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 27018161
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine.
Evidence row 955
CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 20346144
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.
Evidence row 961
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 18187165
Evidence class: insufficient; Study design: Narrative or expert review. Source: The elmiric acids: biologically active anandamide analogs.
Evidence row 962
CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 24751709
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.
Evidence row 969
Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 42144898
Evidence class: insufficient; Study design: Narrative or expert review. Source: Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies.
Evidence row 971
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 972
THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 973
THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 976
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 21309120
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and anxiety.
Evidence row 977
OEA modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 17906678
Evidence class: insufficient; Study design: Narrative or expert review. Source: Novel cannabinoid receptors.
Evidence row 979
Anandamide modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 26411767
Evidence class: insufficient; Study design: Narrative or expert review. Source: TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.
Evidence row 980
Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 36222019
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid signaling in microglia.
Evidence row 982
Endocannabinoids modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31408376
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The TRPV1 channel regulates glucose metabolism.
Evidence row 983
CBD modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 40684872
Evidence class: insufficient; Study design: Animal study. Source: Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.
Evidence row 984
THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31839498
Evidence class: insufficient; Study design: Narrative or expert review. Source: Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.
Evidence row 989
THC modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 990
THC modulates TRPV2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 1004
THC modulates TRPV3; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1006
THCV modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 1016
THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1026
Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 41802611
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.
Evidence row 1030
THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1031
CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 1032
THC modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 1037
THC modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 39368566
Evidence class: mechanistic or pharmacological. Source: Identification of the TRPA1 cannabinoid-binding site.
Evidence row 1038
Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 38219731
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation.
Evidence row 1039
THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 28120232
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Targets of the Phytocannabinoids: A Complex Picture.
Evidence row 1041
Endocannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 25065940
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Evidence row 1048
CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 1051
CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 25269802
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
Evidence row 1056
THC modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 28120232
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Targets of the Phytocannabinoids: A Complex Picture.
Evidence row 1059
Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 39684707
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.
Evidence row 1063
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36150527
Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.
Evidence row 1064
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27516570
Evidence class: insufficient; Study design: Narrative or expert review. Source: Metabolism of endocannabinoids.
Evidence row 1067
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 34126378
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.
Evidence row 1068
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 25461979
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid metabolism by cytochrome P450 monooxygenases.
Evidence row 1072
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 35986066
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB1 receptors regulate salivation.
Evidence row 1074
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 32867595
Evidence class: insufficient; Study design: Narrative or expert review. Source: Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.
Evidence row 1076
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 23512546
Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical probes of endocannabinoid metabolism.
Evidence row 1077
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24325918
Evidence class: insufficient; Study design: Narrative or expert review. Source: Amygdala FAAH and anandamide: mediating protection and recovery from stress.
Evidence row 1078
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 26271952
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Endocannabinoid System and its Modulation by Phytocannabinoids.
Evidence row 1079
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 21418147
Evidence class: insufficient; Study design: Narrative or expert review. Source: The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.
Evidence row 1080
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12505686
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
Evidence row 1081
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 16678907
Evidence class: insufficient; Study design: Narrative or expert review. Source: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
Evidence row 1084
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 39612328
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.
Evidence row 1085
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24768821
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
Evidence row 1086
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36966972
Evidence class: insufficient; Study design: Narrative or expert review. Source: Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.
Evidence row 1087
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36125319
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: 2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice.
Evidence row 1088
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 33450278
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.
Evidence row 1089
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36481187
Evidence class: mechanistic or pharmacological. Source: Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b.
Evidence row 1090
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24676249
Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.
Evidence row 1091
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 38052772
Evidence class: preclinical; Study design: Animal study. Source: A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.
Evidence row 1099
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms). PMID 40274041
Evidence class: insufficient; Study design: Narrative or expert review. Source: The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets?
Evidence row 1109
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 40563990
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.
Evidence row 1113
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 25463999
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Protective effect of palmitoylethanolamide in a rat model of cystitis.
Evidence row 1123
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 10469890
Evidence class: insufficient; Study design: Narrative or expert review. Source: The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?
Evidence row 1124
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 18514375
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of the CB1 receptor in the regulation of sleep.
Evidence row 1128
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 10221757
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors.
Evidence row 1130
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 10574567
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist.
Evidence row 1133
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17459108
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.
Evidence row 1134
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24644287
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.
Evidence row 1135
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27189587
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Endovanilloids are potential activators of the trigeminovascular nocisensor complex.
Evidence row 1139
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 25995819
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells.
Evidence row 1141
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 16760924
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.
Evidence row 1142
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 33568652
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.
Evidence row 1144
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 26408156
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and Their Pharmacological Actions.
Evidence row 1145
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 11259648
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.
Evidence row 1146
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12432948
Evidence class: insufficient; Study design: Narrative or expert review. Source: The cannabinoid receptors.
Evidence row 1147
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17698254
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.
Evidence row 1148
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 16639008
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility.
Evidence row 1150
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15901805
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Evidence row 1151
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 37085778
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model.
Evidence row 1152
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15148262
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.
Evidence row 1154
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15763177
Evidence class: preclinical; Study design: Animal study. Source: Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.
Evidence row 1155
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12356827
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.
Evidence row 1156
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 26408156
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and Their Pharmacological Actions.
Evidence row 1157
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17876300
Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55: a new member of the cannabinoid receptor clan?
Evidence row 1158
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 18514375
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of the CB1 receptor in the regulation of sleep.
Evidence row 1160
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12023533
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Evidence row 1165
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 23789792
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Mechanism of platelet activation induced by endocannabinoids in blood and plasma.
Evidence row 1177
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 35203453
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study.
Evidence row 1180
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 30070030
Evidence class: insufficient. Source: Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight.
Evidence row 1183
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 26707833
Evidence class: mechanistic or pharmacological. Source: Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease.
Evidence row 1187
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 31881191
Evidence class: preclinical; Study design: Animal study. Source: Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation.
Evidence row 1202
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 33537938
Evidence class: insufficient. Source: Cannabinoids and Sleep/Wake Control.

Source Trail

Source-backed evidence table and references

255 research sources

This section is the technical source layer under the overview. It keeps grouped evidence buckets, evidence rows, PubMed or DOI links, related pages, and references visible for audit and revision.

Plain-Language Summary

CB1 is a cannabinoid-relevant target page. The current evidence ledger links it to 339 evidence row(s) from 255 source(s), mostly framed as insufficient (174), mechanistic or pharmacological (147), preclinical (16), preliminary human (2).

Identity

Canonical name: cb1
Type: biological target
Subtype: canonical_cannabinoid_receptor
Description: Not recorded

Evidence Snapshot

Evidence rows: 339
Sources: 255
Evidence classes: insufficient (174), mechanistic or pharmacological (147), preclinical (16), preliminary human (2)
Draft sections: human evidence (1), mechanistic evidence (143), preclinical evidence (14), safety (21), uncertainty (160)

Key Draft Sections

Human evidence: 1 evidence row(s).
Safety and tolerability: 21 evidence row(s).
Uncertainty and gaps: 160 evidence row(s).
Preclinical evidence: 14 evidence row(s).
Mechanistic evidence: 143 evidence row(s).

Ligands And Modulators

Subject	Relationship	Object Or Focus	Evidence Summary	Sources	Evidence Rows
2-AG	studied for	2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic and preclinical research summary: insufficient (6), mechanistic or pharmacological (5), preclinical (1)	12	12 rows (1078-1091)
Anandamide	studied for	anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: insufficient (6), mechanistic or pharmacological (2)	8	8 rows (1063-1077)
Anandamide	modulates	CB2	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (890-894)
Anandamide	modulates	TRPV1	Mapped evidence with interpretation limits: insufficient (1)	1	979
Cannabinoids	studied for	Cannabinoids and immune modulation research outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	276
Cannabinoids	modulates	CB1	Mechanistic research summary: insufficient (13), mechanistic or pharmacological (16)	28	29 rows (806-860)
Cannabinoids	modulates	CB2	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (8)	13	13 rows (864-916)
Cannabinoids	modulates	GPR18	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (944-945)
Cannabinoids	modulates	GPR55	Mapped evidence with interpretation limits: insufficient (4)	4	4 rows (926-934)
Cannabinoids	modulates	receptor, target, or pharmacology mechanisms	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (2)	6	6 rows (206-263)
Cannabinoids	studied for	safety, risk, adverse-event, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	242
Cannabinoids	modulates	TRPA1	Mechanistic research summary: mechanistic or pharmacological (1)	1	1038
Cannabinoids	modulates	TRPV4	Mechanistic research summary: mechanistic or pharmacological (1)	1	1026
CBC	studied for	Inflammation-related outcomes	Mechanistic research summary: mechanistic or pharmacological (3)	3	3 rows (35-76)
CBC	studied for	neurobehavioral, mood, neural stem cell, or neurogenesis outcomes	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (721-723)
CBC	studied for	Pain-related outcomes	Mechanistic and preclinical research summary: insufficient (2), mechanistic or pharmacological (4), preclinical (1)	7	7 rows (684-694)
CBC	studied for	receptor, target, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	284
CBC	modulates	receptor, transporter, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (4)	7	7 rows (662-679)
CBC	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Preclinical research summary: insufficient (1), preclinical (1)	2	2 rows (646-648)
CBC	studied for	Skin and inflammatory dermatology	Mechanistic and preclinical research summary: mechanistic or pharmacological (1), preclinical (1)	2	2 rows (704-711)
CBD	studied for	Endocannabinoids and endocannabinoid-like lipids research topics	Mechanistic research summary: mechanistic or pharmacological (1)	1	292
CBD	modulates	GPR18	Mechanistic research summary: mechanistic or pharmacological (2)	2	2 rows (955-962)
CBD	modulates	GPR55	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (3)	4	4 rows (935-943)
CBD	modulates	receptor, target, or pharmacology mechanisms	Mechanistic and preclinical research summary: insufficient (3), mechanistic or pharmacological (1), preclinical (1)	5	5 rows (253-261)
CBD	studied for	safety, risk, adverse-event, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (340-341)
CBD	modulates	TRP channel activity or ionotropic cannabinoid target mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	361
CBD	modulates	TRPA1	Mapped evidence with interpretation limits: insufficient (1)	1	1031
CBD	modulates	TRPM8	Mapped evidence with interpretation limits: insufficient (1)	1	1048
CBD	modulates	TRPV1	Mapped evidence with interpretation limits: insufficient (1)	1	983
CBDA	studied for	nausea-related or inflammation-related outcomes	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (2)	3	3 rows (43-133)
CBDV	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Preclinical research summary: preclinical (1)	1	203
CBDV	studied for	Seizure and neurodevelopmental outcomes	Mechanistic research summary: mechanistic or pharmacological (1)	1	119
CBG	studied for	Appetite and metabolic outcomes	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)	4	4 rows (620-627)
CBG	studied for	Inflammation-related outcomes	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)	4	4 rows (584-601)
CBG	studied for	Pain-related outcomes	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (31-540)
CBG	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (2)	7	7 rows (563-579)
CBG	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Preclinical research summary: preclinical (1)	1	174
CBG	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (3)	3	3 rows (541-558)
CBG	studied for	Skin and inflammatory dermatology	Preclinical research summary: preclinical (1)	1	607
CBG	modulates	TRPM8	Mechanistic research summary: mechanistic or pharmacological (1)	1	1051
CBN	increases	NREM sleep	Preclinical research summary: preclinical (1)	1	11
CBN	studied for	Pain-related outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	535
CBN	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (2)	7	7 rows (517-524)
CBN	increases	REM sleep	Preclinical research summary: preclinical (1)	1	12
CBN	studied for	safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	514
CBN	studied for	Skin and inflammatory dermatology	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (3)	4	4 rows (525-533)
CBN	modulates	sleep architecture through 11-hydroxy-CBN activity in rats	Mechanistic research summary: mechanistic or pharmacological (1)	1	13
CBN	increases	Total sleep time	Preclinical research summary: preclinical (1)	1	10
Endocannabinoids	studied for	Cannabinoids and immune modulation research outcomes	Mechanistic research summary: mechanistic or pharmacological (1)	1	268
Endocannabinoids	modulates	CB1	Mechanistic research summary: insufficient (11), mechanistic or pharmacological (5)	16	16 rows (814-862)
Endocannabinoids	modulates	CB2	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (4)	7	7 rows (868-908)
Endocannabinoids	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Mechanistic and preclinical research summary: insufficient (1), mechanistic or pharmacological (1), preclinical (2)	4	4 rows (306-313)
Endocannabinoids	studied for	Endocannabinoids and endocannabinoid-like lipids research topics	Mechanistic research summary: mechanistic or pharmacological (1)	1	202
Endocannabinoids	modulates	GPR119	Mapped evidence with interpretation limits: insufficient (1)	1	969
Endocannabinoids	modulates	GPR18	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (1)	5	5 rows (947-961)
Endocannabinoids	modulates	GPR55	Mapped evidence with interpretation limits: insufficient (1)	1	929
Endocannabinoids	modulates	receptor, target, or pharmacology mechanisms	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)	3	3 rows (210-262)
Endocannabinoids	studied for	safety, risk, adverse-event, or formulation-specific concerns	Early human research summary: insufficient (1), preliminary human (1)	2	2 rows (238-343)
Endocannabinoids	modulates	TRPA1	Mechanistic research summary: mechanistic or pharmacological (1)	1	1041
Endocannabinoids	modulates	TRPM8	Mechanistic research summary: mechanistic or pharmacological (1)	1	1059
...	...	...	...	...	38 more bucket(s)

Source-Backed Evidence Table

Evidence Row	Statement	Source
10	CBN increases Total sleep time; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: total sleep time).	A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in ratsPubMed 39528623 DOI 10.1038/s41386-024-02018-7
11	CBN increases NREM sleep; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: NREM sleep).	A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in ratsPubMed 39528623 DOI 10.1038/s41386-024-02018-7
12	CBN increases REM sleep; evidence class: preclinical (population or model: rats; study design: rat polysomnography study; outcome measure: REM sleep).	A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in ratsPubMed 39528623 DOI 10.1038/s41386-024-02018-7
13	CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats; evidence class: mechanistic or pharmacological (population or model: rats; study design: rat and pharmacological study).	A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in ratsPubMed 39528623 DOI 10.1038/s41386-024-02018-7
31	CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
35	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
38	THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes).	The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
39	THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
43	CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes).	Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.PubMed 30627539 DOI 10.1155/2018/1691428
44	THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological (outcome measure: safety, effect, or mechanism claims).	Cannabis Therapeutics and the Future of Neurology.PubMed 30405366 DOI 10.3389/fnint.2018.00051
75	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
76	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
79	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
80	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
81	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes).	Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.PubMed 39968488 DOI 10.26828/cannabis/2024/000206
119	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.PubMed 31447649 DOI 10.3389/fncel.2019.00367
130	CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes).	Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats.PubMed 31897571 DOI 10.1007/s00213-019-05428-4
133	CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: nausea-related or inflammation-related outcomes).	A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.PubMed 24595502 DOI 10.1007/s00213-014-3498-1
174	CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
202	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.PubMed 31325449 DOI 10.1016/j.bcp.2019.07.017
203	CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.PubMed 34179865 DOI 10.1016/j.ibneur.2021.01.004
204	THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
205	THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.PubMed 25220897 DOI 10.1016/j.drugalcdep.2014.08.005
206	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).PubMed 39288632 DOI 10.1016/j.bioorg.2024.107775
207	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	Oxa-adamantyl cannabinoids.PubMed 33636308 DOI 10.1016/j.bmcl.2021.127882
208	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.PubMed 18537620 DOI 10.2174/092986708784567716
210	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.PubMed 30670965 DOI 10.3389/fphar.2018.01496
211	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.PubMed 28826536 DOI 10.1016/bs.apha.2017.04.004
212	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	New Insights in Cannabinoid Receptor Structure and Signaling.PubMed 30767756 DOI 10.2174/1874467212666190215112036
213	THC modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.PubMed 30550613 DOI 10.1167/iovs.18-24838
214	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
216	THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
238	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Adverse Effects of Recreational and Medical Cannabis.PubMed 33897066 DOI 10.64719/pb.4395
242	Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.PubMed 42076122 DOI 10.3390/pharmaceutics18040469
253	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.PubMed 33522084 DOI 10.1111/ejn.15134
254	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.PubMed 23924692 DOI 10.1016/j.neuropharm.2013.07.024
255	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.PubMed 39657242 DOI 10.1093/ijnp/pyae064
256	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabidiol: Pharmaceutical formulations and biomedical applications.PubMed 42212209 DOI 10.22038/ijbms.2026.89134.19592
258	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms).	Cys-loop receptors on cannabinoids: All high?PubMed 36439263 DOI 10.3389/fphys.2022.1044575
261	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.PubMed 22585736 DOI 10.1084/jem.20120242
262	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.PubMed 16107637 DOI 10.1523/jneurosci.0977-05.2005
263	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Mu Opioid Receptors Acutely Regulate Adenosine Signaling in Striatal Glutamate Afferents.PubMed 35091505 DOI 10.1523/jneurosci.1039-21.2022
268	Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes).	Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations.PubMed 40016352 DOI 10.1038/s41593-025-01891-9
276	Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes).	Cannabinoid receptor signaling.PubMed 16596771 DOI 10.1007/3-540-26573-2_2
284	CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
288	THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
289	THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	The Endocannabinoid System and its Modulation by Phytocannabinoids.PubMed 26271952 DOI 10.1007/s13311-015-0374-6
292	CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.PubMed 17965195 DOI 10.1124/mol.107.041863
294	THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.PubMed 17704824 DOI 10.1038/sj.bjp.0707423
303	THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.PubMed 20047159
306	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.PubMed 24346263 DOI 10.1007/s00418-013-1174-x
307	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.PubMed 39245706 DOI 10.1186/s12974-024-03213-5
309	THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Chemical Probes for Investigating the Endocannabinoid System.PubMed 39747798 DOI 10.1007/7854_2024_563
312	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.PubMed 21418147 DOI 10.1111/j.1748-1716.2011.02280.x
313	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.PubMed 30075103 DOI 10.1016/j.bcp.2018.07.042
340	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.PubMed 41008526 DOI 10.3390/biom15091219
341	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids.PubMed 33851375 DOI 10.1055/a-1420-5780
343	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.PubMed 33909195 DOI 10.1007/s11033-021-06366-1
357	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
361	CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
362	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
440	THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes).	Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.PubMed 33228239 DOI 10.3390/biom10111575
457	THC studied for Dependence and withdrawal; evidence class: insufficient (study design: Narrative or expert review; outcome measure: dependence or withdrawal outcomes).	Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence.PubMed 19367504 DOI 10.1080/09540260902782752
465	THC studied for Cognition and memory; evidence class: mechanistic or pharmacological (outcome measure: cognition or memory outcomes).	Acute administration of THC impairs spatial but not associative memory function in zebrafish.PubMed 24639045 DOI 10.1007/s00213-014-3522-5
475	THC studied for Pain-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: pain-related outcomes).	Pharmacology of Medical Cannabis.PubMed 31332738 DOI 10.1007/978-3-030-21737-2_8
514	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].PubMed 27428345
517	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
518	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
519	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
520	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
521	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis.PubMed 10036999 DOI 10.3109/10428199809059244
523	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.PubMed 38673788 DOI 10.3390/ijms25084204
524	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules.PubMed 36091813 DOI 10.3389/fphar.2022.956030
525	CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
527	CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.PubMed 39275884 DOI 10.1002/biof.2122
529	CBN studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.PubMed 38673788 DOI 10.3390/ijms25084204
533	CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons.PubMed 40568800 DOI 10.1021/acs.jmedchem.5c00938
535	CBN studied for Pain-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes).	Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
540	CBG studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
541	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
557	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.PubMed 36497400 DOI 10.3390/cancers14235918
558	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
563	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
568	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
569	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
570	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
571	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.PubMed 42105814 DOI 10.1016/j.bcp.2026.118032
577	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
579	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models.PubMed 41155621 DOI 10.3390/ph18101508
584	CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes).	Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
589	CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes).	Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.PubMed 23415610 DOI 10.1016/j.bcp.2013.01.017
593	CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes).	Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action.PubMed 35614947 DOI 10.3389/fphar.2022.908198
601	CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Animal model mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: inflammation-related or immune outcomes).	The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.PubMed 29562280 DOI 10.1093/ibd/izy014
607	CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
620	CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
621	CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
622	CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.PubMed 42105814 DOI 10.1016/j.bcp.2026.118032
627	CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.PubMed 36397993 DOI 10.1155/2022/3336516
646	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
648	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
662	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
663	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
664	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
667	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
671	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene is a cannabinoid CB2 receptor agonist.PubMed 31368508 DOI 10.1111/bph.14815
675	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.PubMed 39137108 DOI 10.1089/can.2023.0212
679	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.PubMed 23373571 DOI 10.1111/bph.12120
684	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
686	CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
689	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
690	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
691	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
692	CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
694	CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
704	CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
711	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
721	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
723	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
735	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes).	High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain.PubMed 32904155 DOI 10.7717/peerj.9811
736	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
740	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
746	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.PubMed 41947574 DOI 10.1093/alcalc/agag019
750	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.PubMed 25542687 DOI 10.1093/ijnp/pyu094
752	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Case report or case series; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Hair Regrowth with Novel Hemp Extract: A Case Series.PubMed 37305187 DOI 10.4103/ijt.ijt_34_22
754	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents.PubMed 35303507 DOI 10.1016/j.intimp.2022.108693
755	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.PubMed 23712280 DOI 10.1038/nutd.2013.9
756	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.PubMed 31549358 DOI 10.1007/s40263-019-00664-w
757	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.PubMed 36280497 DOI 10.1016/j.tem.2022.08.003
760	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
761	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
763	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
764	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
766	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
767	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.PubMed 25257544 DOI 10.1111/bph.12944
768	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.PubMed 16205722 DOI 10.1038/sj.bjp.0706414
769	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pharmacology of cannabinoids in the treatment of epilepsy.PubMed 28087250 DOI 10.1016/j.yebeh.2016.11.016
770	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.PubMed 41008636 DOI 10.3390/biom15091329
771	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.PubMed 30170189 DOI 10.1016/j.phrs.2018.08.021
772	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
775	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.PubMed 23902479 DOI 10.1111/bph.12322
777	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.PubMed 25542687 DOI 10.1093/ijnp/pyu094
781	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.PubMed 34500785 DOI 10.3390/molecules26175352
784	THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
788	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
789	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.PubMed 25542687 DOI 10.1093/ijnp/pyu094
793	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.PubMed 26362774 DOI 10.1093/ijnp/pyv092
796	THCV studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
798	THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
806	Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Oxa-adamantyl cannabinoids.PubMed 33636308 DOI 10.1016/j.bmcl.2021.127882
807	Cannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.PubMed 18537620 DOI 10.2174/092986708784567716
808	THC modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
809	HHC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Crystal structures of agonist-bound human cannabinoid receptor CB1.PubMed 40866700 DOI 10.1038/s41586-025-09454-5
810	THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.PubMed 35489334 DOI 10.1016/j.cell.2022.04.005
811	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism.PubMed 38101408 DOI 10.1016/j.cell.2023.11.017
812	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	A cryptic pocket in CB1 drives peripheral and functional selectivity.PubMed 40044849 DOI 10.1038/s41586-025-08618-7
813	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.PubMed 28527758 DOI 10.1016/j.neuropharm.2017.05.018
814	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
815	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Assay of CB1 Receptor Binding.PubMed 27245890 DOI 10.1007/978-1-4939-3539-0_5
816	THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.PubMed 38830102 DOI 10.1073/pnas.2321532121
817	Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Pharmacology of cannabinoid receptor ligands.PubMed 10469884
818	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.PubMed 27879006 DOI 10.1002/med.21418
819	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	The CB1 cannabinoid receptor in the brain.PubMed 9974174 DOI 10.1006/nbdi.1998.0215
820	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	CB1 Cannabinoid Receptor Signaling and Biased Signaling.PubMed 34500853 DOI 10.3390/molecules26175413
821	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.PubMed 30333554 DOI 10.1038/s41401-018-0164-x
822	THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.PubMed 22343625 DOI 10.1074/jbc.m111.316463
823	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.PubMed 38675703 DOI 10.3390/molecules29081881
824	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Allosteric modulation of the cannabinoid CB1 receptor.PubMed 16113085 DOI 10.1124/mol.105.016162
825	THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.PubMed 31968549 DOI 10.3390/molecules25020417
826	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.PubMed 28103441 DOI 10.1021/acschemneuro.6b00310
827	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Endocannabinoids and Their Pharmacological Actions.PubMed 26408156 DOI 10.1007/978-3-319-20825-1_1
828	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	The future of type 1 cannabinoid receptor allosteric ligands.PubMed 29355038 DOI 10.1080/03602532.2018.1428341
829	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).PubMed 25162172 DOI 10.1021/jm501042u
830	HHC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Crystal structures of agonist-bound human cannabinoid receptor CB1.PubMed 28678776 DOI 10.1038/nature23272
831	Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.PubMed 29355030 DOI 10.1080/03602532.2018.1428342
832	THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Synthetic Cannabinoids.PubMed 26132518 DOI 10.1097/maj.0000000000000466
833	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.PubMed 39828030 DOI 10.1016/j.pharmthera.2025.108795
834	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Structural mechanism of CB1R binding to peripheral and biased inverse agonists.PubMed 39695122 DOI 10.1038/s41467-024-54206-0
835	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Targeting mechanosensitive cannabinoid receptor 1 with isoflavone prodrugs attenuates atherosclerotic endothelial dysfunction.PubMed 41559687 DOI 10.1186/s12929-026-01214-5
836	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.PubMed 40521518 DOI 10.1021/acsomega.4c11355
837	THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.PubMed 33811300 DOI 10.1007/s12272-021-01326-6
838	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist.PubMed 31490743 DOI 10.2174/0929867326666190906155339
839	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	New Insights in Cannabinoid Receptor Structure and Signaling.PubMed 30767756 DOI 10.2174/1874467212666190215112036
840	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.PubMed 28527758 DOI 10.1016/j.neuropharm.2017.05.018
841	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?PubMed 20590557 DOI 10.1111/j.1476-5381.2010.00777.x
842	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.PubMed 34050525 DOI 10.1007/s43440-021-00270-y
843	THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Endocannabinoid System: A Multi-Facet Therapeutic Target.PubMed 27086601 DOI 10.2174/1574884711666160418105339
844	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a.PubMed 17895407 DOI 10.1124/mol.107.039263
845	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities.PubMed 31771126 DOI 10.3390/ijms20235874
846	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	The pharmacology of cannabinoid receptors and their ligands: an overview.PubMed 16570099 DOI 10.1038/sj.ijo.0803272
847	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Latest advances in cannabinoid receptor agonists.PubMed 19939187 DOI 10.1517/13543770903436505
848	THC modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.PubMed 19285266 DOI 10.1016/j.beem.2008.09.003
849	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.PubMed 31461639 DOI 10.1016/j.ejphar.2019.172628
850	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	The endocannabinoid system: physiology and pharmacology.PubMed 15550444 DOI 10.1093/alcalc/agh110
851	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism.PubMed 36088492 DOI 10.1038/s41386-022-01436-9
852	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment.PubMed 35429587 DOI 10.1016/j.neulet.2022.136634
853	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models.PubMed 40855505 DOI 10.1186/s40035-025-00500-w
854	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Adipocyte cannabinoid CB1 receptor deficiency alleviates high fat diet-induced memory deficit, depressive-like behavior, neuroinflammation and impairment in adult neurogenesis.PubMed 31491589 DOI 10.1016/j.psyneuen.2019.104418
855	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.PubMed 25967266 DOI 10.1016/j.neuroscience.2015.05.002
856	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	A cannabinoid link between mitochondria and memory.PubMed 27828947 DOI 10.1038/nature20127
857	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome.PubMed 39300547 DOI 10.1186/s13229-024-00617-1
858	THC modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species.PubMed 31165913 DOI 10.1007/s00213-019-05283-3
859	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus.PubMed 35595026 DOI 10.1016/j.nlm.2022.107638
860	Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Adenosine receptors are the on-and-off switch of astrocytic cannabinoid type 1 (CB1) receptor effect upon synaptic plasticity in the medial prefrontal cortex.PubMed 38482984 DOI 10.1002/glia.24518
861	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.PubMed 36613469 DOI 10.3390/ijms24010026
862	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice.PubMed 16596773 DOI 10.1007/3-540-26573-2_4
863	THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
864	Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).PubMed 39288632 DOI 10.1016/j.bioorg.2024.107775
865	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.PubMed 18537620 DOI 10.2174/092986708784567716
866	THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
867	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabichromene is a cannabinoid CB2 receptor agonist.PubMed 31368508 DOI 10.1111/bph.14815
868	Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
869	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Pharmacology of cannabinoid receptor ligands.PubMed 10469884
871	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay.PubMed 40271066 DOI 10.3389/fphar.2025.1469986
872	Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Functional Selectivity at Cannabinoid Receptors.PubMed 28826535 DOI 10.1016/bs.apha.2017.03.005
873	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Pharmacology of cannabinoid CB1 and CB2 receptors.PubMed 9336020 DOI 10.1016/s0163-7258(97
874	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.PubMed 26124120 DOI 10.1073/pnas.1503395112
875	Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The Spicy Story of Cannabimimetic Indoles.PubMed 34684770 DOI 10.3390/molecules26206190
876	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Crystal Structure of the Human Cannabinoid Receptor CB2.PubMed 30639103 DOI 10.1016/j.cell.2018.12.011
877	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.PubMed 32004460 DOI 10.1016/j.cell.2020.01.007
880	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.PubMed 33749323 DOI 10.1152/ajprenal.00065.2021
883	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	CB2 cannabinoid receptor mediation of antinociception.PubMed 16563625 DOI 10.1016/j.pain.2005.12.018
886	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats.PubMed 27608434 DOI 10.1016/j.eplepsyres.2016.08.011
889	Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).PubMed 38886185 DOI 10.1080/13543776.2024.2368745
890	Anandamide modulates CB2; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.PubMed 16678907 DOI 10.1016/j.plipres.2006.03.003
893	THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.PubMed 29980914 DOI 10.1007/164_2018_143
894	Anandamide modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Structural requirements for cannabinoid receptor probes.PubMed 16596776 DOI 10.1007/3-540-26573-2_7
901	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation.PubMed 36475439 DOI 10.1098/rspb.2022.1941
903	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.PubMed 18615177 DOI 10.2174/157015907780866884
906	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.PubMed 37286073 DOI 10.1016/j.neuropharm.2023.109601
907	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.PubMed 26824325 DOI 10.18632/oncotarget.7042
908	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.PubMed 23960212 DOI 10.1093/cercor/bht202
911	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.PubMed 12823482 DOI 10.1046/j.1460-9568.2003.02704.x
913	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation.PubMed 36583304 DOI 10.1002/ptr.7710
914	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.PubMed 41875735 DOI 10.1016/j.phymed.2026.158068
916	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy.PubMed 41383775 DOI 10.1101/2025.11.26.690750
922	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.PubMed 18247131 DOI 10.1007/s11481-007-9077-z
926	Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.PubMed 28826536 DOI 10.1016/bs.apha.2017.04.004
927	THC modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
929	Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.PubMed 35862111 DOI 10.1002/jcp.30837
932	Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	GPR55 - a putative "type 3" cannabinoid receptor in inflammation.PubMed 26669245 DOI 10.1515/jbcpp-2015-0080
933	Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Cannabinoid receptor ligand bias: implications in the central nervous system.PubMed 27835801 DOI 10.1016/j.coph.2016.10.005
934	Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?PubMed 20370712 DOI 10.2174/156802610791164229
935	CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).PubMed 35083862 DOI 10.1111/bcpt.13710
936	CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.PubMed 17704827 DOI 10.1038/sj.bjp.0707419
938	THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	GPR55: a new member of the cannabinoid receptor clan?PubMed 17876300 DOI 10.1038/sj.bjp.0707464
939	THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Pharmacological characterization of GPR55, a putative cannabinoid receptor.PubMed 20298715 DOI 10.1016/j.pharmthera.2010.02.004
940	CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	The orphan receptor GPR55 is a novel cannabinoid receptor.PubMed 17876302 DOI 10.1038/sj.bjp.0707460
943	CBD modulates GPR55; evidence class: mechanistic or pharmacological (outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors.PubMed 36016551 DOI 10.3389/fphar.2022.945935
944	Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.PubMed 28826536 DOI 10.1016/bs.apha.2017.04.004
945	Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoid receptor ligand bias: implications in the central nervous system.PubMed 27835801 DOI 10.1016/j.coph.2016.10.005
947	Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoids in Gynecological Diseases.PubMed 34676329 DOI 10.1159/000499164
948	Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.PubMed 42114685 DOI 10.1016/j.bcp.2026.118038
949	THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.PubMed 29902723 DOI 10.1016/j.ejmech.2018.05.050
952	Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.PubMed 29098189 DOI 10.1089/can.2017.0036
953	Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine.PubMed 27018161 DOI 10.7717/peerj.1835
955	CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.PubMed 20346144 DOI 10.1186/1471-2202-11-44
961	Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	The elmiric acids: biologically active anandamide analogs.PubMed 18187165 DOI 10.1016/j.neuropharm.2007.11.011
962	CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.PubMed 24751709 DOI 10.1016/j.ejphar.2014.03.055
969	Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies.PubMed 42144898 DOI 10.1111/bph.70511
971	THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
972	THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
973	THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
976	THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoids and anxiety.PubMed 21309120 DOI 10.1007/7854_2009_16
977	OEA modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Novel cannabinoid receptors.PubMed 17906678 DOI 10.1038/sj.bjp.0707481
979	Anandamide modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.PubMed 26411767 DOI 10.2174/1570159x13666150216222543
980	Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Endocannabinoid signaling in microglia.PubMed 36222019 DOI 10.1002/glia.24281
982	Endocannabinoids modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	The TRPV1 channel regulates glucose metabolism.PubMed 31408376 DOI 10.1152/ajpendo.00102.2019
983	CBD modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.PubMed 40684872 DOI 10.1016/j.pnpbp.2025.111456
984	THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.PubMed 31839498 DOI 10.1016/j.yebeh.2019.106832
989	THC modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
990	THC modulates TRPV2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
1004	THC modulates TRPV3; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1006	THCV modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
1016	THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1026	Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.PubMed 41802611 DOI 10.1016/j.freeradbiomed.2026.02.059
1030	THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1031	CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
1032	THC modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
1037	THC modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Identification of the TRPA1 cannabinoid-binding site.PubMed 39368566 DOI 10.1016/j.phrs.2024.107444
1038	Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation.PubMed 38219731 DOI 10.1055/a-2244-8855
1039	THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Molecular Targets of the Phytocannabinoids: A Complex Picture.PubMed 28120232 DOI 10.1007/978-3-319-45541-9_4
1041	Endocannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.PubMed 25065940 DOI 10.1016/j.bmc.2014.07.006
1048	CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
1051	CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
1056	THC modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Molecular Targets of the Phytocannabinoids: A Complex Picture.PubMed 28120232 DOI 10.1007/978-3-319-45541-9_4
1059	Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.PubMed 39684707 DOI 10.3390/ijms252313000
1063	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.PubMed 36150527 DOI 10.1016/j.plipres.2022.101194
1064	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Metabolism of endocannabinoids.PubMed 27516570 DOI 10.5604/17322693.1213898
1067	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.PubMed 34126378 DOI 10.1016/j.plefa.2021.102311
1068	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Endocannabinoid metabolism by cytochrome P450 monooxygenases.PubMed 25461979 DOI 10.1016/j.prostaglandins.2014.11.002
1072	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Cannabinoid CB1 receptors regulate salivation.PubMed 35986066 DOI 10.1038/s41598-022-17987-2
1074	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.PubMed 32867595 DOI 10.1146/annurev-pharmtox-030220-112741
1076	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Chemical probes of endocannabinoid metabolism.PubMed 23512546 DOI 10.1124/pr.112.006387
1077	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Amygdala FAAH and anandamide: mediating protection and recovery from stress.PubMed 24325918 DOI 10.1016/j.tips.2013.08.008
1078	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The Endocannabinoid System and its Modulation by Phytocannabinoids.PubMed 26271952 DOI 10.1007/s13311-015-0374-6
1079	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.PubMed 21418147 DOI 10.1111/j.1748-1716.2011.02280.x
1080	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
1081	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.PubMed 16678907 DOI 10.1016/j.plipres.2006.03.003
1084	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.PubMed 39612328 DOI 10.1126/sciadv.adq4779
1085	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.PubMed 24768821 DOI 10.1016/j.exger.2014.04.008
1086	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.PubMed 36966972 DOI 10.1016/j.pharmthera.2023.108394
1087	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice.PubMed 36125319 DOI 10.1111/acer.14949
1088	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.PubMed 33450278 DOI 10.1016/j.neuropharm.2021.108450
1089	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b.PubMed 36481187 DOI 10.1016/j.expneurol.2022.114292
1090	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.PubMed 24676249 DOI 10.1039/c4cs00047a
1091	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.PubMed 38052772 DOI 10.1038/s41467-023-43606-3
1099	OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms).	The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets?PubMed 40274041 DOI 10.1016/j.physbeh.2025.114929
1109	PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms).	Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.PubMed 40563990 DOI 10.3390/biomedicines13061271
1113	PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms).	Protective effect of palmitoylethanolamide in a rat model of cystitis.PubMed 25463999 DOI 10.1016/j.juro.2014.11.083
1123	Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms).	The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?PubMed 10469890
1124	Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms).	The role of the CB1 receptor in the regulation of sleep.PubMed 18514375 DOI 10.1016/j.pnpbp.2008.04.008
1128	Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms).	Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors.PubMed 10221757 DOI 10.1016/s0028-3908(98
1130	Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms).	The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist.PubMed 10574567 DOI 10.1097/00001756-199910190-00021
1133	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.PubMed 17459108 DOI 10.1111/j.1460-9568.2007.05521.x
1134	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.PubMed 24644287 DOI 10.1074/jbc.m113.536953
1135	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Endovanilloids are potential activators of the trigeminovascular nocisensor complex.PubMed 27189587 DOI 10.1186/s10194-016-0644-7
1139	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells.PubMed 25995819 DOI 10.4062/biomolther.2014.137
1141	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.PubMed 16760924 DOI 10.1038/sj.npp.1301118
1142	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.PubMed 33568652 DOI 10.1038/s41467-021-20946-6
1144	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Endocannabinoids and Their Pharmacological Actions.PubMed 26408156 DOI 10.1007/978-3-319-20825-1_1
1145	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.PubMed 11259648 DOI 10.1073/pnas.061029898
1146	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The cannabinoid receptors.PubMed 12432948 DOI 10.1016/s0090-6980(02
1147	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.PubMed 17698254 DOI 10.1016/j.neuint.2007.06.033
1148	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility.PubMed 16639008 DOI 10.1167/iovs.05-0729
1150	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.PubMed 15901805 DOI 10.1124/jpet.105.085282
1151	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model.PubMed 37085778 DOI 10.1186/s10194-023-01580-7
1152	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.PubMed 15148262 DOI 10.1038/sj.bjp.0705789
1154	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.PubMed 15763177 DOI 10.1016/j.brainresbull.2004.12.002
1155	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.PubMed 12356827
1156	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Endocannabinoids and Their Pharmacological Actions.PubMed 26408156 DOI 10.1007/978-3-319-20825-1_1
1157	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	GPR55: a new member of the cannabinoid receptor clan?PubMed 17876300 DOI 10.1038/sj.bjp.0707464
1158	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The role of the CB1 receptor in the regulation of sleep.PubMed 18514375 DOI 10.1016/j.pnpbp.2008.04.008
1160	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.PubMed 12023533 DOI 10.1124/jpet.301.3.1020
1165	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Mechanism of platelet activation induced by endocannabinoids in blood and plasma.PubMed 23789792 DOI 10.3109/09537104.2013.803530
1177	LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms).	The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study.PubMed 35203453 DOI 10.3390/biomedicines10020243
1180	LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms).	Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight.PubMed 30070030 DOI 10.1002/oby.22245
1183	LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms).	Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease.PubMed 26707833 DOI 10.1016/j.phrs.2015.12.009
1187	SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms).	Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation.PubMed 31881191 DOI 10.1016/j.bcp.2019.113783
1202	Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms).	Cannabinoids and Sleep/Wake Control.PubMed 33537938 DOI 10.1007/978-3-030-61663-2_6

2-AG
Anandamide
Appetite and metabolic outcomes
CB2
CBC
CBD
CBDA
CBDV
CBG
CBN
Cannabinoids
Cognition and memory
Dependence and withdrawal
Endocannabinoids
GPR119
GPR18
GPR55
HHC
Inflammation-related outcomes
LEA

References

A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in ratsPubMed 39528623 DOI 10.1038/s41386-024-02018-7
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.PubMed 30627539 DOI 10.1155/2018/1691428
Cannabis Therapeutics and the Future of Neurology.PubMed 30405366 DOI 10.3389/fnint.2018.00051
Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.PubMed 39968488 DOI 10.26828/cannabis/2024/000206
Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.PubMed 31447649 DOI 10.3389/fncel.2019.00367
Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats.PubMed 31897571 DOI 10.1007/s00213-019-05428-4
A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.PubMed 24595502 DOI 10.1007/s00213-014-3498-1
The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.PubMed 31325449 DOI 10.1016/j.bcp.2019.07.017
Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.PubMed 34179865 DOI 10.1016/j.ibneur.2021.01.004
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.PubMed 25220897 DOI 10.1016/j.drugalcdep.2014.08.005
Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).PubMed 39288632 DOI 10.1016/j.bioorg.2024.107775
Oxa-adamantyl cannabinoids.PubMed 33636308 DOI 10.1016/j.bmcl.2021.127882
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.PubMed 18537620 DOI 10.2174/092986708784567716
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.PubMed 30670965 DOI 10.3389/fphar.2018.01496
Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.PubMed 28826536 DOI 10.1016/bs.apha.2017.04.004
New Insights in Cannabinoid Receptor Structure and Signaling.PubMed 30767756 DOI 10.2174/1874467212666190215112036
Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.PubMed 30550613 DOI 10.1167/iovs.18-24838
Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
Adverse Effects of Recreational and Medical Cannabis.PubMed 33897066 DOI 10.64719/pb.4395
Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.PubMed 42076122 DOI 10.3390/pharmaceutics18040469
Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.PubMed 33522084 DOI 10.1111/ejn.15134
Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.PubMed 23924692 DOI 10.1016/j.neuropharm.2013.07.024
A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.PubMed 39657242 DOI 10.1093/ijnp/pyae064
Cannabidiol: Pharmaceutical formulations and biomedical applications.PubMed 42212209 DOI 10.22038/ijbms.2026.89134.19592
Cys-loop receptors on cannabinoids: All high?PubMed 36439263 DOI 10.3389/fphys.2022.1044575
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.PubMed 22585736 DOI 10.1084/jem.20120242
Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.PubMed 16107637 DOI 10.1523/jneurosci.0977-05.2005
Mu Opioid Receptors Acutely Regulate Adenosine Signaling in Striatal Glutamate Afferents.PubMed 35091505 DOI 10.1523/jneurosci.1039-21.2022
Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations.PubMed 40016352 DOI 10.1038/s41593-025-01891-9
Cannabinoid receptor signaling.PubMed 16596771 DOI 10.1007/3-540-26573-2_2
In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
The Endocannabinoid System and its Modulation by Phytocannabinoids.PubMed 26271952 DOI 10.1007/s13311-015-0374-6
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.PubMed 17965195 DOI 10.1124/mol.107.041863
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.PubMed 17704824 DOI 10.1038/sj.bjp.0707423
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.PubMed 20047159
Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.PubMed 24346263 DOI 10.1007/s00418-013-1174-x
Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.PubMed 39245706 DOI 10.1186/s12974-024-03213-5
Chemical Probes for Investigating the Endocannabinoid System.PubMed 39747798 DOI 10.1007/7854_2024_563
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.PubMed 21418147 DOI 10.1111/j.1748-1716.2011.02280.x
Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.PubMed 30075103 DOI 10.1016/j.bcp.2018.07.042
Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.PubMed 41008526 DOI 10.3390/biom15091219
Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids.PubMed 33851375 DOI 10.1055/a-1420-5780
Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.PubMed 33909195 DOI 10.1007/s11033-021-06366-1
Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.PubMed 33228239 DOI 10.3390/biom10111575
Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence.PubMed 19367504 DOI 10.1080/09540260902782752
Acute administration of THC impairs spatial but not associative memory function in zebrafish.PubMed 24639045 DOI 10.1007/s00213-014-3522-5
Pharmacology of Medical Cannabis.PubMed 31332738 DOI 10.1007/978-3-030-21737-2_8
[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].PubMed 27428345
Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis.PubMed 10036999 DOI 10.3109/10428199809059244
Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.PubMed 38673788 DOI 10.3390/ijms25084204
Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules.PubMed 36091813 DOI 10.3389/fphar.2022.956030
Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.PubMed 39275884 DOI 10.1002/biof.2122
Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons.PubMed 40568800 DOI 10.1021/acs.jmedchem.5c00938
The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.PubMed 36497400 DOI 10.3390/cancers14235918
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.PubMed 42105814 DOI 10.1016/j.bcp.2026.118032
The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models.PubMed 41155621 DOI 10.3390/ph18101508
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.PubMed 23415610 DOI 10.1016/j.bcp.2013.01.017
Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action.PubMed 35614947 DOI 10.3389/fphar.2022.908198
The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.PubMed 29562280 DOI 10.1093/ibd/izy014
Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.PubMed 36397993 DOI 10.1155/2022/3336516
Cannabichromene is a cannabinoid CB2 receptor agonist.PubMed 31368508 DOI 10.1111/bph.14815
Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.PubMed 39137108 DOI 10.1089/can.2023.0212
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.PubMed 23373571 DOI 10.1111/bph.12120
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain.PubMed 32904155 DOI 10.7717/peerj.9811
Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.PubMed 41947574 DOI 10.1093/alcalc/agag019
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.PubMed 25542687 DOI 10.1093/ijnp/pyu094
Hair Regrowth with Novel Hemp Extract: A Case Series.PubMed 37305187 DOI 10.4103/ijt.ijt_34_22
Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents.PubMed 35303507 DOI 10.1016/j.intimp.2022.108693
The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.PubMed 23712280 DOI 10.1038/nutd.2013.9
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.PubMed 31549358 DOI 10.1007/s40263-019-00664-w
Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.PubMed 36280497 DOI 10.1016/j.tem.2022.08.003
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.PubMed 25257544 DOI 10.1111/bph.12944
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.PubMed 16205722 DOI 10.1038/sj.bjp.0706414
Pharmacology of cannabinoids in the treatment of epilepsy.PubMed 28087250 DOI 10.1016/j.yebeh.2016.11.016
Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.PubMed 41008636 DOI 10.3390/biom15091329
Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.PubMed 30170189 DOI 10.1016/j.phrs.2018.08.021
Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.PubMed 23902479 DOI 10.1111/bph.12322
An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.PubMed 34500785 DOI 10.3390/molecules26175352
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.PubMed 26362774 DOI 10.1093/ijnp/pyv092
Crystal structures of agonist-bound human cannabinoid receptor CB1.PubMed 40866700 DOI 10.1038/s41586-025-09454-5
Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.PubMed 35489334 DOI 10.1016/j.cell.2022.04.005
Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism.PubMed 38101408 DOI 10.1016/j.cell.2023.11.017
A cryptic pocket in CB1 drives peripheral and functional selectivity.PubMed 40044849 DOI 10.1038/s41586-025-08618-7
Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.PubMed 28527758 DOI 10.1016/j.neuropharm.2017.05.018
Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
Assay of CB1 Receptor Binding.PubMed 27245890 DOI 10.1007/978-1-4939-3539-0_5
Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.PubMed 38830102 DOI 10.1073/pnas.2321532121
Pharmacology of cannabinoid receptor ligands.PubMed 10469884
Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.PubMed 27879006 DOI 10.1002/med.21418
The CB1 cannabinoid receptor in the brain.PubMed 9974174 DOI 10.1006/nbdi.1998.0215
CB1 Cannabinoid Receptor Signaling and Biased Signaling.PubMed 34500853 DOI 10.3390/molecules26175413
Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.PubMed 30333554 DOI 10.1038/s41401-018-0164-x
Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.PubMed 22343625 DOI 10.1074/jbc.m111.316463
CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.PubMed 38675703 DOI 10.3390/molecules29081881
Allosteric modulation of the cannabinoid CB1 receptor.PubMed 16113085 DOI 10.1124/mol.105.016162
Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.PubMed 31968549 DOI 10.3390/molecules25020417
Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.PubMed 28103441 DOI 10.1021/acschemneuro.6b00310
Endocannabinoids and Their Pharmacological Actions.PubMed 26408156 DOI 10.1007/978-3-319-20825-1_1
The future of type 1 cannabinoid receptor allosteric ligands.PubMed 29355038 DOI 10.1080/03602532.2018.1428341
Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).PubMed 25162172 DOI 10.1021/jm501042u
Crystal structures of agonist-bound human cannabinoid receptor CB1.PubMed 28678776 DOI 10.1038/nature23272
Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.PubMed 29355030 DOI 10.1080/03602532.2018.1428342
Synthetic Cannabinoids.PubMed 26132518 DOI 10.1097/maj.0000000000000466
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.PubMed 39828030 DOI 10.1016/j.pharmthera.2025.108795
Structural mechanism of CB1R binding to peripheral and biased inverse agonists.PubMed 39695122 DOI 10.1038/s41467-024-54206-0
Targeting mechanosensitive cannabinoid receptor 1 with isoflavone prodrugs attenuates atherosclerotic endothelial dysfunction.PubMed 41559687 DOI 10.1186/s12929-026-01214-5
Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.PubMed 40521518 DOI 10.1021/acsomega.4c11355
Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.PubMed 33811300 DOI 10.1007/s12272-021-01326-6
Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist.PubMed 31490743 DOI 10.2174/0929867326666190906155339
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?PubMed 20590557 DOI 10.1111/j.1476-5381.2010.00777.x
Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.PubMed 34050525 DOI 10.1007/s43440-021-00270-y
Endocannabinoid System: A Multi-Facet Therapeutic Target.PubMed 27086601 DOI 10.2174/1574884711666160418105339
CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a.PubMed 17895407 DOI 10.1124/mol.107.039263
Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities.PubMed 31771126 DOI 10.3390/ijms20235874
The pharmacology of cannabinoid receptors and their ligands: an overview.PubMed 16570099 DOI 10.1038/sj.ijo.0803272
Latest advances in cannabinoid receptor agonists.PubMed 19939187 DOI 10.1517/13543770903436505
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.PubMed 19285266 DOI 10.1016/j.beem.2008.09.003
Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.PubMed 31461639 DOI 10.1016/j.ejphar.2019.172628
The endocannabinoid system: physiology and pharmacology.PubMed 15550444 DOI 10.1093/alcalc/agh110
Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism.PubMed 36088492 DOI 10.1038/s41386-022-01436-9
Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment.PubMed 35429587 DOI 10.1016/j.neulet.2022.136634
Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models.PubMed 40855505 DOI 10.1186/s40035-025-00500-w
Adipocyte cannabinoid CB1 receptor deficiency alleviates high fat diet-induced memory deficit, depressive-like behavior, neuroinflammation and impairment in adult neurogenesis.PubMed 31491589 DOI 10.1016/j.psyneuen.2019.104418
Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.PubMed 25967266 DOI 10.1016/j.neuroscience.2015.05.002
A cannabinoid link between mitochondria and memory.PubMed 27828947 DOI 10.1038/nature20127
Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome.PubMed 39300547 DOI 10.1186/s13229-024-00617-1
The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species.PubMed 31165913 DOI 10.1007/s00213-019-05283-3
Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus.PubMed 35595026 DOI 10.1016/j.nlm.2022.107638
Adenosine receptors are the on-and-off switch of astrocytic cannabinoid type 1 (CB1) receptor effect upon synaptic plasticity in the medial prefrontal cortex.PubMed 38482984 DOI 10.1002/glia.24518
Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.PubMed 36613469 DOI 10.3390/ijms24010026
Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice.PubMed 16596773 DOI 10.1007/3-540-26573-2_4
A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay.PubMed 40271066 DOI 10.3389/fphar.2025.1469986
Functional Selectivity at Cannabinoid Receptors.PubMed 28826535 DOI 10.1016/bs.apha.2017.03.005
Pharmacology of cannabinoid CB1 and CB2 receptors.PubMed 9336020 DOI 10.1016/s0163-7258(97
CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.PubMed 26124120 DOI 10.1073/pnas.1503395112
The Spicy Story of Cannabimimetic Indoles.PubMed 34684770 DOI 10.3390/molecules26206190
Crystal Structure of the Human Cannabinoid Receptor CB2.PubMed 30639103 DOI 10.1016/j.cell.2018.12.011
Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.PubMed 32004460 DOI 10.1016/j.cell.2020.01.007
CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.PubMed 33749323 DOI 10.1152/ajprenal.00065.2021
CB2 cannabinoid receptor mediation of antinociception.PubMed 16563625 DOI 10.1016/j.pain.2005.12.018
The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats.PubMed 27608434 DOI 10.1016/j.eplepsyres.2016.08.011
Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).PubMed 38886185 DOI 10.1080/13543776.2024.2368745
Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.PubMed 16678907 DOI 10.1016/j.plipres.2006.03.003
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.PubMed 29980914 DOI 10.1007/164_2018_143
Structural requirements for cannabinoid receptor probes.PubMed 16596776 DOI 10.1007/3-540-26573-2_7
Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation.PubMed 36475439 DOI 10.1098/rspb.2022.1941
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.PubMed 18615177 DOI 10.2174/157015907780866884
Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.PubMed 37286073 DOI 10.1016/j.neuropharm.2023.109601
Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.PubMed 26824325 DOI 10.18632/oncotarget.7042
CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.PubMed 23960212 DOI 10.1093/cercor/bht202
Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.PubMed 12823482 DOI 10.1046/j.1460-9568.2003.02704.x
Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation.PubMed 36583304 DOI 10.1002/ptr.7710
A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.PubMed 41875735 DOI 10.1016/j.phymed.2026.158068
CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy.PubMed 41383775 DOI 10.1101/2025.11.26.690750
The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.PubMed 18247131 DOI 10.1007/s11481-007-9077-z
Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.PubMed 35862111 DOI 10.1002/jcp.30837
GPR55 - a putative "type 3" cannabinoid receptor in inflammation.PubMed 26669245 DOI 10.1515/jbcpp-2015-0080
Cannabinoid receptor ligand bias: implications in the central nervous system.PubMed 27835801 DOI 10.1016/j.coph.2016.10.005
GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?PubMed 20370712 DOI 10.2174/156802610791164229
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).PubMed 35083862 DOI 10.1111/bcpt.13710
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.PubMed 17704827 DOI 10.1038/sj.bjp.0707419
GPR55: a new member of the cannabinoid receptor clan?PubMed 17876300 DOI 10.1038/sj.bjp.0707464
Pharmacological characterization of GPR55, a putative cannabinoid receptor.PubMed 20298715 DOI 10.1016/j.pharmthera.2010.02.004
The orphan receptor GPR55 is a novel cannabinoid receptor.PubMed 17876302 DOI 10.1038/sj.bjp.0707460
Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors.PubMed 36016551 DOI 10.3389/fphar.2022.945935
Cannabinoids in Gynecological Diseases.PubMed 34676329 DOI 10.1159/000499164
Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.PubMed 42114685 DOI 10.1016/j.bcp.2026.118038
Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.PubMed 29902723 DOI 10.1016/j.ejmech.2018.05.050
An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.PubMed 29098189 DOI 10.1089/can.2017.0036
GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine.PubMed 27018161 DOI 10.7717/peerj.1835
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.PubMed 20346144 DOI 10.1186/1471-2202-11-44
The elmiric acids: biologically active anandamide analogs.PubMed 18187165 DOI 10.1016/j.neuropharm.2007.11.011
Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.PubMed 24751709 DOI 10.1016/j.ejphar.2014.03.055
Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies.PubMed 42144898 DOI 10.1111/bph.70511
Cannabinoids and anxiety.PubMed 21309120 DOI 10.1007/7854_2009_16
Novel cannabinoid receptors.PubMed 17906678 DOI 10.1038/sj.bjp.0707481
TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.PubMed 26411767 DOI 10.2174/1570159x13666150216222543
Endocannabinoid signaling in microglia.PubMed 36222019 DOI 10.1002/glia.24281
The TRPV1 channel regulates glucose metabolism.PubMed 31408376 DOI 10.1152/ajpendo.00102.2019
Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.PubMed 40684872 DOI 10.1016/j.pnpbp.2025.111456
Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.PubMed 31839498 DOI 10.1016/j.yebeh.2019.106832
Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.PubMed 41802611 DOI 10.1016/j.freeradbiomed.2026.02.059
Identification of the TRPA1 cannabinoid-binding site.PubMed 39368566 DOI 10.1016/j.phrs.2024.107444
Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation.PubMed 38219731 DOI 10.1055/a-2244-8855
Molecular Targets of the Phytocannabinoids: A Complex Picture.PubMed 28120232 DOI 10.1007/978-3-319-45541-9_4
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.PubMed 25065940 DOI 10.1016/j.bmc.2014.07.006
TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.PubMed 39684707 DOI 10.3390/ijms252313000
Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.PubMed 36150527 DOI 10.1016/j.plipres.2022.101194
Metabolism of endocannabinoids.PubMed 27516570 DOI 10.5604/17322693.1213898
The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.PubMed 34126378 DOI 10.1016/j.plefa.2021.102311
Endocannabinoid metabolism by cytochrome P450 monooxygenases.PubMed 25461979 DOI 10.1016/j.prostaglandins.2014.11.002
Cannabinoid CB1 receptors regulate salivation.PubMed 35986066 DOI 10.1038/s41598-022-17987-2
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.PubMed 32867595 DOI 10.1146/annurev-pharmtox-030220-112741
Chemical probes of endocannabinoid metabolism.PubMed 23512546 DOI 10.1124/pr.112.006387
Amygdala FAAH and anandamide: mediating protection and recovery from stress.PubMed 24325918 DOI 10.1016/j.tips.2013.08.008
Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.PubMed 39612328 DOI 10.1126/sciadv.adq4779
Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.PubMed 24768821 DOI 10.1016/j.exger.2014.04.008
Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.PubMed 36966972 DOI 10.1016/j.pharmthera.2023.108394
2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice.PubMed 36125319 DOI 10.1111/acer.14949
The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.PubMed 33450278 DOI 10.1016/j.neuropharm.2021.108450
Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b.PubMed 36481187 DOI 10.1016/j.expneurol.2022.114292
Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.PubMed 24676249 DOI 10.1039/c4cs00047a
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.PubMed 38052772 DOI 10.1038/s41467-023-43606-3
The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets?PubMed 40274041 DOI 10.1016/j.physbeh.2025.114929
Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.PubMed 40563990 DOI 10.3390/biomedicines13061271
Protective effect of palmitoylethanolamide in a rat model of cystitis.PubMed 25463999 DOI 10.1016/j.juro.2014.11.083
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?PubMed 10469890
The role of the CB1 receptor in the regulation of sleep.PubMed 18514375 DOI 10.1016/j.pnpbp.2008.04.008
Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors.PubMed 10221757 DOI 10.1016/s0028-3908(98
The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist.PubMed 10574567 DOI 10.1097/00001756-199910190-00021
Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.PubMed 17459108 DOI 10.1111/j.1460-9568.2007.05521.x
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.PubMed 24644287 DOI 10.1074/jbc.m113.536953
Endovanilloids are potential activators of the trigeminovascular nocisensor complex.PubMed 27189587 DOI 10.1186/s10194-016-0644-7
A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells.PubMed 25995819 DOI 10.4062/biomolther.2014.137
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.PubMed 16760924 DOI 10.1038/sj.npp.1301118
Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.PubMed 33568652 DOI 10.1038/s41467-021-20946-6
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.PubMed 11259648 DOI 10.1073/pnas.061029898
The cannabinoid receptors.PubMed 12432948 DOI 10.1016/s0090-6980(02
Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.PubMed 17698254 DOI 10.1016/j.neuint.2007.06.033
Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility.PubMed 16639008 DOI 10.1167/iovs.05-0729
The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.PubMed 15901805 DOI 10.1124/jpet.105.085282
Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model.PubMed 37085778 DOI 10.1186/s10194-023-01580-7
Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.PubMed 15148262 DOI 10.1038/sj.bjp.0705789
Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.PubMed 15763177 DOI 10.1016/j.brainresbull.2004.12.002
Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.PubMed 12356827
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.PubMed 12023533 DOI 10.1124/jpet.301.3.1020
Mechanism of platelet activation induced by endocannabinoids in blood and plasma.PubMed 23789792 DOI 10.3109/09537104.2013.803530
The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study.PubMed 35203453 DOI 10.3390/biomedicines10020243
Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight.PubMed 30070030 DOI 10.1002/oby.22245
Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease.PubMed 26707833 DOI 10.1016/j.phrs.2015.12.009
Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation.PubMed 31881191 DOI 10.1016/j.bcp.2019.113783
Cannabinoids and Sleep/Wake Control.PubMed 33537938 DOI 10.1007/978-3-030-61663-2_6

CB1 has research behind it, but the bucket matters.

What the CB1 research is usually about

CB1

CB1

CB2

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

CB2

Evidence buckets before the source table

Keep reading around this topic

Read safety context beside the research guide.

CB1 Evidence Review: the long-form source walk-through

Start with the research question

Where this page has the most source density

Bucket chapters: what the literature is circling

CB1

CB1

CB2

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

CB2

Pain-related outcomes

Receptor, target, metabolic, and pharmacology mechanisms

Human evidence, mechanisms, and safety are different lanes

What this does and does not mean

How to use the source table

Source-reading checklist for CB1

CB1 source-by-source reading notes

Source-backed evidence table and references

Plain-Language Summary

Identity

Evidence Snapshot

Key Draft Sections

Ligands And Modulators

Source-Backed Evidence Table

Related Pages

References